155 related articles for article (PubMed ID: 27132782)
1. Neurocognitive clinical outcome assessments for inborn errors of metabolism and other rare conditions.
Shapiro E; Bernstein J; Adams HR; Barbier AJ; Buracchio T; Como P; Delaney KA; Eichler F; Goldsmith JC; Hogan M; Kovacs S; Mink JW; Odenkirchen J; Parisi MA; Skrinar A; Waisbren SE; Mulberg AE
Mol Genet Metab; 2016 Jun; 118(2):65-9. PubMed ID: 27132782
[TBL] [Abstract][Full Text] [Related]
2. Developing treatments for inborn errors: incentives available to the clinician.
Haffner ME
Mol Genet Metab; 2004 Apr; 81 Suppl 1():S63-6. PubMed ID: 15050976
[TBL] [Abstract][Full Text] [Related]
3. Patient-Reported Outcome and Observer-Reported Outcome Assessment in Rare Disease Clinical Trials: An ISPOR COA Emerging Good Practices Task Force Report.
Benjamin K; Vernon MK; Patrick DL; Perfetto E; Nestler-Parr S; Burke L
Value Health; 2017; 20(7):838-855. PubMed ID: 28712612
[TBL] [Abstract][Full Text] [Related]
4. Pharmacotherapy of inborn errors of metabolism illustrating challenges in orphan diseases.
Das AM
J Pharmacol Toxicol Methods; 2016; 81():9-14. PubMed ID: 26921514
[TBL] [Abstract][Full Text] [Related]
5. Expanding research to provide an evidence base for nutritional interventions for the management of inborn errors of metabolism.
Camp KM; Lloyd-Puryear MA; Yao L; Groft SC; Parisi MA; Mulberg A; Gopal-Srivastava R; Cederbaum S; Enns GM; Ershow AG; Frazier DM; Gohagan J; Harding C; Howell RR; Regan K; Stacpoole PW; Venditti C; Vockley J; Watson M; Coates PM
Mol Genet Metab; 2013 Aug; 109(4):319-28. PubMed ID: 23806236
[TBL] [Abstract][Full Text] [Related]
6. Therapies for inborn errors of metabolism: what has the orphan drug act delivered?
Talele SS; Xu K; Pariser AR; Braun MM; Farag-El-Massah S; Phillips MI; Thompson BH; Coté TR
Pediatrics; 2010 Jul; 126(1):101-6. PubMed ID: 20566615
[TBL] [Abstract][Full Text] [Related]
7. Research challenges in central nervous system manifestations of inborn errors of metabolism.
Dickson PI; Pariser AR; Groft SC; Ishihara RW; McNeil DE; Tagle D; Griebel DJ; Kaler SG; Mink JW; Shapiro EG; Bjoraker KJ; Krivitzky L; Provenzale JM; Gropman A; Orchard P; Raymond G; Cohen BH; Steiner RD; Goldkind SF; Nelson RM; Kakkis E; Patterson MC
Mol Genet Metab; 2011 Mar; 102(3):326-38. PubMed ID: 21176882
[TBL] [Abstract][Full Text] [Related]
8. Clinical experience with orphan drugs for rare metabolic diseases.
Caso-González A; Núñez-Rodríguez J; Nebot-Villacampa MJ; González-Pérez Y; Marín-Gorricho R; Leralta-González C; Obaldia-Alaña C
An Pediatr (Engl Ed); 2022 Jan; 96(1):8-16. PubMed ID: 34992005
[TBL] [Abstract][Full Text] [Related]
9. An analysis of FDA-approved drugs for metabolic diseases.
Kinch MS; Umlauf S; Plummer M
Drug Discov Today; 2015 Jun; 20(6):648-51. PubMed ID: 25680688
[TBL] [Abstract][Full Text] [Related]
10. Development of clinical guidelines for inborn errors of metabolism: commentary.
Vockley J; Chapman KA; Arnold GL
Mol Genet Metab; 2013 Apr; 108(4):203-5. PubMed ID: 23428739
[TBL] [Abstract][Full Text] [Related]
11. The individual (single patient) IND for inborn errors of metabolism.
Dickson PI; Tolar J
Mol Genet Metab; 2015; 116(1-2):1-3. PubMed ID: 25456747
[TBL] [Abstract][Full Text] [Related]
12. Inborn errors of metabolism: medical and administrative "orphans".
Winter SC; Buist NR
Am J Manag Care; 1998 Aug; 4(8):1164-8. PubMed ID: 10182891
[TBL] [Abstract][Full Text] [Related]
13. Development of medicines for rare diseases and inborn errors of metabolism: Toward novel public-private partnerships.
Rosenberg N; Stolwijk NN; van den Berg S; Heus JJ; van der Wel V; van Gelder T; Bosch AM; de Visser SJ; Hollak CEM
J Inherit Metab Dis; 2023 Sep; 46(5):806-816. PubMed ID: 36938792
[TBL] [Abstract][Full Text] [Related]
14. SIMD statement on investigational new drugs for rare disease therapies.
Longo N
Mol Genet Metab; 2012 Mar; 105(3):367. PubMed ID: 22300846
[No Abstract] [Full Text] [Related]
15. DDIEM: drug database for inborn errors of metabolism.
Abdelhakim M; McMurray E; Syed AR; Kafkas S; Kamau AA; Schofield PN; Hoehndorf R
Orphanet J Rare Dis; 2020 Jun; 15(1):146. PubMed ID: 32527280
[TBL] [Abstract][Full Text] [Related]
16. Development of precision therapies for rare inborn errors of metabolism: Functional investigations in cell culture models.
Didiasova M; Banning A; Tikkanen R
J Inherit Metab Dis; 2024 May; 47(3):509-516. PubMed ID: 37606592
[TBL] [Abstract][Full Text] [Related]
17. Neonatal screening for inborn errors of metabolism: cost, yield and outcome.
Pollitt RJ; Green A; McCabe CJ; Booth A; Cooper NJ; Leonard JV; Nicholl J; Nicholson P; Tunaley JR; Virdi NK
Health Technol Assess; 1997; 1(7):i-iv, 1-202. PubMed ID: 9483160
[TBL] [Abstract][Full Text] [Related]
18. Thirteen year retrospective review of the spectrum of inborn errors of metabolism presenting in a tertiary center in Saudi Arabia.
Alfadhel M; Benmeakel M; Hossain MA; Al Mutairi F; Al Othaim A; Alfares AA; Al Balwi M; Alzaben A; Eyaid W
Orphanet J Rare Dis; 2016 Sep; 11(1):126. PubMed ID: 27629047
[TBL] [Abstract][Full Text] [Related]
19. The importance of anthropological methods in the diagnosis of rare diseases.
Różdżyńska-Świątkowska A; Tylki-Szymańska A
J Pediatr Endocrinol Metab; 2019 Apr; 32(4):311-320. PubMed ID: 30917104
[TBL] [Abstract][Full Text] [Related]
20. Normal vitamin D levels and bone mineral density among children with inborn errors of metabolism consuming medical food-based diets.
Geiger KE; Koeller DM; Harding CO; Huntington KL; Gillingham MB
Nutr Res; 2016 Jan; 36(1):101-8. PubMed ID: 26773786
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
